Literature DB >> 2981586

Neutrophils autoinactivate secretory products by myeloperoxidase-catalyzed oxidation.

R A Clark, N Borregaard.   

Abstract

The neutrophil response to inflammatory stimuli involves the formation of reactive oxygen species and secretion of granule enzymes. In studying secretion of vitamin B12 binding protein by human neutrophils, we noted a major decrease in total recoverable activity from the extracellular fluid plus the stimulated cells (54% of resting cells). Recovery of B12 binding protein from neutrophils exposed to phorbol myristate acetate or opsonized zymosan was significantly enhanced on addition of heme enzyme inhibitors (azide, cyanide) or catalase or when halide-free medium was used. The changes in B12 binding protein recovery were attributable entirely to increases in extracellular fluid levels, and cell pellet content was unaffected. These data indicate extracellular destruction of functional B12 binding protein by the halide-dependent heme enzyme myeloperoxidase and H2O2. Kinetic studies demonstrated rapid secretion of B12 binding protein in the first two to five minutes, followed by its inactivation over the next 20 to 30 minutes. A cell-free extract of vitamin B12 binding protein was readily inactivated on exposure to purified myeloperoxidase, H2O2, and a halide. These findings document a functional interaction among products of the neutrophil specific granules (B12 binding protein), azurophil granules (myeloperoxidase), and metabolic burst (H2O2). They provide an interesting model for the modulation of the inflammatory response by oxidation of secretory products of neutrophils.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981586

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Subcellular localization and release of human neutrophil gelatinase, confirming the existence of separate gelatinase-containing granules.

Authors:  L Kjeldsen; O W Bjerrum; J Askaa; N Borregaard
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

2.  Action of hypochlorous acid on the antioxidant protective enzymes superoxide dismutase, catalase and glutathione peroxidase.

Authors:  O I Aruoma; B Halliwell
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

3.  Oxidative inactivation of myeloperoxidase released from human neutrophils.

Authors:  S W Edwards; H L Nurcombe; C A Hart
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

4.  Myeloperoxidase-dependent oxidative inactivation of neutrophil neutral proteinases and microbicidal enzymes.

Authors:  M C Vissers; C C Winterbourn
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

5.  Mobilization of sialidase from intracellular stores to the surface of human neutrophils and its role in stimulated adhesion responses of these cells.

Authors:  A S Cross; D G Wright
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 6.  Myeloperoxidase in human neutrophil host defence.

Authors:  William M Nauseef
Journal:  Cell Microbiol       Date:  2014-06-19       Impact factor: 3.715

7.  Detection of anti-myeloperoxidase antibodies in the serum of patients with type 1 diabetes mellitus.

Authors:  A Accardo-Palumbo; G Triolo; E Giardina; M C Carbone; A Ferrante; G Triolo
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

8.  Human neutrophil gelatinase is a component of specific granules.

Authors:  M S Hibbs; D F Bainton
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

Review 9.  The function of the NADPH oxidase of phagocytes and its relationship to other NOXs in plants, invertebrates, and mammals.

Authors:  Anthony W Segal
Journal:  Int J Biochem Cell Biol       Date:  2007-10-09       Impact factor: 5.085

10.  Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphatase.

Authors:  N Borregaard; L Christensen; O W Bejerrum; H S Birgens; I Clemmensen
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.